Table 2.
Relationship between PCAT19 expression level and clinical characteristics of lung cancer patients.
| Variables | Patients (n = 74) | PCAT19 expression | χ 2 | P | |
|---|---|---|---|---|---|
| High (n = 40) | Low (n = 34) | ||||
| Age (years) | 0.031 | 0.859∗ | |||
| <60 | 34 | 18 (52.94%) | 16 (47.06%) | ||
| ≥60 | 40 | 22 (55.00%) | 18 (45.00%) | ||
| Gender | — | 0.719# | |||
| Male | 66 | 35 (58.33%) | 31 (46.97%) | ||
| Female | 8 | 5 (62.50%) | 3 (37.50%) | ||
| Tumor size (cm) | 7.551 | 0.006∗ | |||
| <5 | 30 | 22 (73.33%) | 8 (26.67%) | ||
| ≥5 | 44 | 18 (40.91%) | 26 (59.09%) | ||
| Pathology | 8.867 | 0.012∗ | |||
| LUAD | 35 | 18 (51.43%) | 17 (48.57%) | ||
| LUSC | 24 | 18 (75.00%) | 6 (25.00%) | ||
| Large-cell carcinoma | 15 | 4 (26.67%) | 11 (73.33%) | ||
| Clinical stage | 0.641 | 0.423∗ | |||
| I-II | 45 | 26 (57.78%) | 19 (42.22%) | ||
| III-IV | 29 | 14 (48.28%) | 15 (51.72%) | ||
| Lymph node metastasis | 0.804 | 0.370∗ | |||
| Yes | 35 | 17 (48.57%) | 18 (51.43%) | ||
| No | 39 | 23 (58.97%) | 16 (41.03%) | ||
∗ P: chi-squared test; #P: Fisher exact test.